Shares of Celcuity, Inc. (NASDAQ:CELC – Get Free Report) reached a new 52-week high during trading on Tuesday . Wolfe Research assumed coverage on shares of Celcuity in a research report on Tuesday, November 18th. Wells Fargo & Company assumed coverage on shares of Celcuity in a research report on Friday, December 12th. Also, Director David Dalvey sold 20,000 shares of Celcuity stock in a transaction that occurred on Tuesday, January 27th. Celcuity Company Profile(Get Free Report)Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics.